Claims for Patent: 7,125,862
✉ Email this page to a colleague
Summary for Patent: 7,125,862
Title: | Porphyrin-metal complexes and oxygen infusions containing the same |
Abstract: | A porphyrin metal complex that can form a stable oxygen complex and acts effectively as an oxygen infusion, which comprises: a transition metal ion M of period 4 or 5 coordinating to a porphyrin derivative represented by the following general ##STR00001## wherein R.sup.1 is an alicyclic hydrocarbon group which may contain a substituent, R.sup.2 is an alkylene group and R.sup.3 is a group which does not hinder the coordination of an imidazolyl group to M. |
Inventor(s): | Tsuchida; Eishun (Tokyo, JP), Komatsu; Teruyuki (Tokyo, JP), Matsukawa; Yasuko (Tokyo, JP) |
Assignee: | Japan Science and Technology Agency (Saitama, JP) |
Application Number: | 10/485,381 |
Patent Claims: | 1. A porphyrin metal complex comprising: a transition metal ion M of period 4 or 5 coordinating to a porphyrin derivative represented by the following general formula [I]
##STR00007## wherein R.sup.1 is an alicyclic hydrocarbon group selected from the group consisting of a 1-substituted cyclopropyl group, a 1-substituted cyclopentyl group, a 1-substituted cyclohexyl group, a 1-methyl-2-cyclohexenyl group, a 1-substiuted
norbornyl group and a 1-substituted adamatyl group, R.sup.2 is an alkylene group and R.sup.3 is a group which does not hinder the coordination of an imidazolyl group to M.
2. A porphyrin metal complex represented by the following general formula [II]: ##STR00008## wherein M is a transition metal of period 4 or 5, R.sup.1 is an alicyclic hydrocarbon group selected from the group consisting of a 1-substituted cyclopropyl group, a 1-substituted evelopentyl group, a 1-substituted cyclohexyl group, a 1-methyl-2-cyclohexenyl group, a 1-substiuted norbomyl group and a 1-substituted adamatyl group, R.sup.2 is an alkylene group, R.sup.3 is a group that does not hinder the coordination of the imidazolyl group to M, X.sup.31 is a halogen ion and n denotes a number obtained by subtracting 2 from the valence number of M. 3. The porphyrin metal complex of claim 1, wherein R.sup.2 is a C.sub.2 to C.sub.10 alkylene group. 4. The porphyrin metal complex of claim 1, wherein R.sup.3 is a hydrogen atom or a substituent selected from the group consisting of a methyl group, an ethyl group and a propyl group. 5. The porphyrin metal complex of claim 1, wherein M is Fe or Co. 6. The porphyrin metal complex of claim 5, wherein M is Fe(II) or Fe(III). 7. The porphyrin metal complex of claim 5, wherein M is Co(II). 8. An oxygen infusion composition comprising at least two components, at least one of which is a porphyrin metal complex of claim 1. 9. An oxygen infusion composition prepared by incorporating and binding at least the porphyrin metal complex of claim 1 in a phospholipid vesicle, a fatty oil microsphere, albumin or an albumin multimer. 10. An oxygen infusion composition prepared by incorporating at least the porphyrin metal complex of claim 1 into human serum albumin, recombinant human serum albumin, human serum albumin dimer or recombinant human serum albumin dimer. 11. The porphyrin metal complex of claim 2, wherein R.sup.2 is a C.sub.2 to C.sub.10 alkylene group. 12. The porphyrin metal complex of claim 2, wherein R.sup.3 is a hydrogen atom or a substituent selected from the group consisting of a methyl group, an ethyl group and a propyl group. 13. The porphyrin metal complex of claim 3, wherein R.sup.3 is a hydrogen atom or a substituent selected from the group consisting of a methyl group, an ethyl group and a propyl group. 14. The porphyrin metal complex of claim 2, wherein M is Fe or Co. 15. The porphyrin metal complex of claim 3, wherein M is Fe or Co. 16. The porphyrin metal complex of claim 4, wherein M is Fe or Co. 17. An oxygen infusion composition comprising at least two components, at least one of which is a porphyrin metal complex of claim 2. 18. An oxygen infusion composition comprising at least two components, at least one of which is a porphyrin metal complex of claim 3. 19. An oxygen infusion composition comprising at least two components, at least one of which is a porphyrin metal complex of claim 4. 20. An oxygen infusion composition comprising at least two components, at least one of which is a porphyrin metal complex of claim 5. 21. An oxygen infusion composition comprising at least two components, at least one of which is a porphyrin metal complex of claim 6. 22. An oxygen infusion composition comprising at least two components, at least one of which is a porphyrin metal complex of claim 7. 23. An oxygen infusion composition prepared by incorporating and binding at least the porphyrin metal complex of claim 2 in a phospholipid vesicle, a fatty oil microsphere, albumin or an albumin multimer. 24. An oxygen infusion composition prepared by incorporating and binding at least the porphyrin metal complex of claim 3 in a phospholipid vesicle, a fatty oil microsphere, albumin or an albumin multimer. 25. An oxygen infusion composition prepared by incorporating and binding at least the porphyrin metal complex of claim 4 in a phospholipid vesicle, a fatty oil microsphere, albumin or an albumin multimer. 26. An oxygen infusion composition prepared by incorporating and binding at least the porphyrin metal complex of claim 5 in a phospholipid vesicle, a fatty oil microsphere, albumin or an albumin multimer. 27. An oxygen infusion composition prepared by incorporating and binding at least the porphyrin metal complex of claim 6 in a phospholipid vesicle, a fatty oil microsphere, albumin or an albumin multimer. 28. An oxygen infusion composition prepared by incorporating and binding at least the porphyrin metal complex of claim 7 in a phospholipid vesicle, a fatty oil microsphere, albumin or an albumin multimer. 29. An oxygen infusion composition prepared by incorporating at least the porphyrin metal complex of claim 2 into human serum albumin, recombinant human serum albumin, human serum albumin dimer or recombinant human serum albumin dimer. 30. An oxygen infusion composition prepared by incorporating at least the porphyrin metal complex of claim 3 into human serum albumin, recombinant human serum albumin, human serum albumin dimer or recombinant human serum albumin dimer. 31. An oxygen infusion composition prepared by incorporating at least the porphyrin metal complex of claim 4 into human serum albumin, recombinant human serum albumin, human serum albumin dimer or recombinant human serum albumin dimer. 32. An oxygen infusion composition prepared by incorporating at least the porphyrin metal complex of claim 5 into human serum albumin, recombinant human serum albumin, human serum albumin dimer or recombinant human serum albumin dimer. 33. An oxygen infusion composition prepared by incorporating at least the porphyrin metal complex of claim 6 into human serum albumin, recombinant human serum albumin, human serum albumin dimer or recombinant human serum albumin dimer. 34. An oxygen infusion composition prepared by incorporating at least the porphyrin metal complex of claim 7 into human serum albumin, recombinant human serum albumin, human serum albumin dimer or recombinant human serum albumin dimer. |
Details for Patent 7,125,862
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Grifols Therapeutics Llc | ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5 | albumin (human) | For Injection | 101138 | 10/21/1942 | ⤷ Try a Trial | 2021-07-30 |
Baxalta Us Inc. | BUMINATE, FLEXBUMIN | albumin (human) | Injection | 101452 | 03/03/1954 | ⤷ Try a Trial | 2021-07-30 |
Csl Behring Ag | ALBURX | albumin (human) | Injection | 102366 | 07/23/1976 | ⤷ Try a Trial | 2021-07-30 |
Grifols Biologicals Llc | ALBUTEIN | albumin (human) | Injection | 102478 | 08/15/1978 | ⤷ Try a Trial | 2021-07-30 |
Instituto Grifols, S.a. | HUMAN ALBUMIN GRIFOLS | albumin (human) | Injection | 103352 | 02/17/1995 | ⤷ Try a Trial | 2021-07-30 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.